Capital DailyCapital Daily
Markets · Investing · Business
Capital DailyCapital Daily
Finance

Arm vs. Credo Technology Group: Which Semiconductor Stock Is a Better Buy in 2026?

Arm earns royalties every time a chip uses its architecture, while Credo builds the connectivity that links those chips inside AI data centers. Both are essential to the AI build-out, but only one is growing at a triple-digit pace.

Arm vs. Credo Technology Group: Which Semiconductor Stock Is a Better Buy in 2026?

Published September 11, 2026 · Category: Finance

Overview

As demand for artificial intelligence accelerates, investors are weighing the merits of Arm (NASDAQ:ARM) and Credo Technology Group (NASDAQ:CRDO). Choosing between them requires deciding which business model is the better buy.

Arm provides the essential blueprints for modern processors, while Credo focuses on the high-speed connections that allow those processors to talk to each other. Both companies are vital to the data center infrastructure that powers the modern web, making them popular choices for investors seeking exposure to the semiconductor industry.

Details

Arm designs and licenses the fundamental architecture used in nearly every smartphone on the planet. In its latest annual report, filed for the fiscal year ended March 31, 2026, the company highlights its position among semiconductor stocks, generating royalties from chipmakers in various sectors. This asset-light model allows the business to reach end markets like data centers and vehicles without the heavy costs of manufacturing hardware.

Continue reading

Source

Originally published at www.fool.com.

Related Articles

CD
Capital Daily Newsroom

Capital Daily covers markets, crypto and commodities for Asia & the Middle East — tier-1 desk research, AI-driven analysis, institutional-grade data. Tip our newsroom: [email protected]

Email the newsroom →
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.